| 06/02/2026 10:40 |
[Delayed]Corporate Governance Report |
| 06/02/2026 10:00 |
Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026 |
| 05/22/2026 16:40 |
Notice Regarding Results of Capital Increase by way of Third-Party Allotment (Not Implemented) |
| 05/13/2026 13:00 |
Presentation Material Conference on FY2025 Financial Results |
| 05/13/2026 13:00 |
Supplementary Financial Data (IFRS) for the Year Ended March 31, 2026 |
| 05/13/2026 13:00 |
Summary of Consolidated Financial Results for the Year Ended March 31, 2026 [IFRS] |
| 04/27/2026 11:30 |
Notice regarding Withdrawal of Shelf Registration Statement for Issuance of New Shares |
| 04/20/2026 17:30 |
Notice Regarding Determination of Issue Price, Selling Price and Other Matters |
| 04/08/2026 16:00 |
Notice Regarding Issuance of New Shares and Secondary Offering of Shares |
| 04/08/2026 16:00 |
Notice Regarding Refinancing of Existing Borrowings through a Bridge Loan |
| 03/02/2026 15:41 |
Presentation Material (Boost 2028 - Accelerating Strong Sumitomo Pharma -) |
| 03/02/2026 15:41 |
Sumitomo Pharma Announces Boost 2028 - Accelerating Strong Sumitomo Pharma - |
| 03/02/2026 15:41 |
Announcement of Filing of Shelf Registration Statement for Issuance of New Shares |
| 03/02/2026 15:41 |
Sumitomo Pharma Announces Revisions to Its Financial Forecasts |
| 02/17/2026 15:00 |
Publication of Materials from the R&D Meeting for Analysts, Investors, and Media |
| 02/13/2026 17:20 |
Regarding the Scheduled Review in Japan of the Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells (AMCHEPRY) |
| 01/30/2026 15:30 |
Presentation Material (Conference on Q3 FY2025 Financial Results) |
| 01/30/2026 15:30 |
Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2026 |
| 01/30/2026 15:30 |
Summary of Consolidated Financial Results for the Nine Months Ended December 31, 2025 [IFRS] |
| 12/15/2025 11:00 |
Sumitomo Pharma Selected as Highest Rating A-List Company by CDP for Two Consecutive Years in the Category of Climate Change in the CDP 2025 |
| 12/09/2025 13:00 |
Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the ASH 2025 |
| 10/31/2025 15:30 |
Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2026 |
| 10/31/2025 15:30 |
Presentation Material (Conference on Q2 FY2025 Financial Results) |
| 10/31/2025 15:30 |
Summary of Consolidated Financial Results for the Second Quarter (First Half) of the Year Ending March 31, 2026 [IFRS] |
| 10/31/2025 15:30 |
(Progress of Disclosure Matters) Confirmation of Gain on Sales of Shares of Subsidiaries in connection with the Company Split of Asian Business |
| 10/31/2025 15:30 |
Sumitomo Pharma Announces Variances Between Its Financial Forecasts for the Half-Year Ended September 30, 2025, and Revisions to Financial Forecasts |
| 08/05/2025 11:30 |
Submission of the Application of Manufacturing and Marketing Authorization for iPS Cell-Derived dopaminergic neural progenitor cells in Japan |
| 07/31/2025 15:30 |
Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2026 |
| 07/31/2025 15:30 |
Presentation Material (Conference on Q1 FY2025 Financial Results) |
| 07/31/2025 15:30 |
Notice Concerning Finance Costs |
| 07/31/2025 15:30 |
(Progress of Disclosure Matters) Completion of Procedures for Company Split of Asian Business and Share Transfer to Marubeni Global Pharma |
| 07/31/2025 15:30 |
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2026 [IFRS] |
| 07/01/2025 11:20 |
Corporate Governance Report |
| 06/26/2025 17:30 |
Notice of Assignment of Assets for Key Products in the U.S. within Sumitomo Pharma Group |
| 06/26/2025 17:30 |
Matters Concerning Controlling Shareholders, Etc. |
